Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report

Fixed dosage regimen is currently the standard therapy with tyrosine kinase inhibitors (TKI). This case report demonstrates successful determination of nilotinib dosage by therapeutic drug monitoring (TDM) in a patient with chronic myeloid leukemia (CML). TDM may provide useful marker for individual...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakahara, Ryosuke, Sumimoto, Takahiro, Ogata, Masao, Sato, Yuhki, Itoh, Hiroki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637326/
https://www.ncbi.nlm.nih.gov/pubmed/31360502
http://dx.doi.org/10.1002/ccr3.2191
_version_ 1783436220767928320
author Nakahara, Ryosuke
Sumimoto, Takahiro
Ogata, Masao
Sato, Yuhki
Itoh, Hiroki
author_facet Nakahara, Ryosuke
Sumimoto, Takahiro
Ogata, Masao
Sato, Yuhki
Itoh, Hiroki
author_sort Nakahara, Ryosuke
collection PubMed
description Fixed dosage regimen is currently the standard therapy with tyrosine kinase inhibitors (TKI). This case report demonstrates successful determination of nilotinib dosage by therapeutic drug monitoring (TDM) in a patient with chronic myeloid leukemia (CML). TDM may provide useful marker for individualized dosing of TKI for the treatment of CML.
format Online
Article
Text
id pubmed-6637326
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-66373262019-07-29 Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report Nakahara, Ryosuke Sumimoto, Takahiro Ogata, Masao Sato, Yuhki Itoh, Hiroki Clin Case Rep Case Reports Fixed dosage regimen is currently the standard therapy with tyrosine kinase inhibitors (TKI). This case report demonstrates successful determination of nilotinib dosage by therapeutic drug monitoring (TDM) in a patient with chronic myeloid leukemia (CML). TDM may provide useful marker for individualized dosing of TKI for the treatment of CML. John Wiley and Sons Inc. 2019-06-14 /pmc/articles/PMC6637326/ /pubmed/31360502 http://dx.doi.org/10.1002/ccr3.2191 Text en © 2019 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case Reports
Nakahara, Ryosuke
Sumimoto, Takahiro
Ogata, Masao
Sato, Yuhki
Itoh, Hiroki
Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report
title Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report
title_full Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report
title_fullStr Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report
title_full_unstemmed Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report
title_short Successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: A case report
title_sort successful determination of nilotinib dosage by therapeutic drug monitoring in a patient with chronic myeloid leukemia developing hepatic dysfunction: a case report
topic Case Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6637326/
https://www.ncbi.nlm.nih.gov/pubmed/31360502
http://dx.doi.org/10.1002/ccr3.2191
work_keys_str_mv AT nakahararyosuke successfuldeterminationofnilotinibdosagebytherapeuticdrugmonitoringinapatientwithchronicmyeloidleukemiadevelopinghepaticdysfunctionacasereport
AT sumimototakahiro successfuldeterminationofnilotinibdosagebytherapeuticdrugmonitoringinapatientwithchronicmyeloidleukemiadevelopinghepaticdysfunctionacasereport
AT ogatamasao successfuldeterminationofnilotinibdosagebytherapeuticdrugmonitoringinapatientwithchronicmyeloidleukemiadevelopinghepaticdysfunctionacasereport
AT satoyuhki successfuldeterminationofnilotinibdosagebytherapeuticdrugmonitoringinapatientwithchronicmyeloidleukemiadevelopinghepaticdysfunctionacasereport
AT itohhiroki successfuldeterminationofnilotinibdosagebytherapeuticdrugmonitoringinapatientwithchronicmyeloidleukemiadevelopinghepaticdysfunctionacasereport

Ejemplares similares